Partnership

PEP-Therapy values collaborations and partnerships with pharma and biotech partners, clinical organizations and investors to accelerate the development of its flagship product, PEP-010.

PEP-Therapy is also open to R&D collaborations combining our cell-penetrating shuttles with your assets to further enhance or achieve intracellular delivery.

PEP-Therapy is currently strengthening its pipeline of peptide-based products in oncology through co-developments or licensing-in programs with academic institutions and biotech companies.